
At SGO 2026, Alison Schram, MD, highlighted first-in-class tumor suppressor reactivation and emphasized early NGS testing in ovarian cancer.
Alison is a gynecologic medical oncologist. This includes cervical, fallopian tube, ovarian, uterine (endometrial), vaginal, and vulvar cancers.
She is an early drug development specialist and has special training in research studies, also known as clinical trials.